Search results
Sanofi reaches agreement with Novavax regarding COVID-19 vaccine
WFMZ Eastern Pennsylvania and Western New Jersey· 4 days agoThe agreement involves co-commercializing the COVID-19 vaccine, developing novel COVID-19-Influenza...
AstraZeneca pulls its COVID-19 vaccine from the European market
WSLS Newschannel 10 Roanoke· 7 days agoThe pharma giant AstraZeneca has requested that the European authorization for its COVID-19 vaccine...
Novavax stock doubles after Sanofi deal marks 'new chapter' for company
Yahoo Finance· 4 days agoNovavax stock (NVAX) skyrocketed on Friday, nearly doubling on the news French drug and vaccine...
Novavax Reports First Quarter 2024 Financial Results and Operational Highlights
NBC 17 Raleigh· 5 days agoAnnounces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-& ...
Novavax stock jumps 50% as Sanofi deal kicks off turning point for struggling vaccine maker
CNBC· 1 day agoA vial labelled "Novavax V COVID-19 Vaccine" is seen in this illustration taken January 16, 2022....
...Human Language, Why AstraZeneca Has Taken Its COVID-19 Vaccine Off The Market, And Much More This...
IFLScience· 4 days agoThis week, the “near-collapse” of Earth’s magnetic field 590 million years ago may have helped...
Earnings call: Vaxart posts progress in vaccine trials, Q1 financials By Investing.com
Investing.com· 1 day agoVaxart, Inc. (NASDAQ: NASDAQ:VXRT), a biotechnology company specializing in the development of oral...
Countries struggle to draft 'pandemic treaty' to avoid mistakes made during COVID
Houston Chronicle· 5 days agoAfter the coronavirus pandemic triggered once-unthinkable lockdowns, upended economies and killed...
Cancer Vaccine Triggers Fierce Immune Response to Fight Malignant Brain Tumors in Human Patients
GoodNewsNetwork· 4 days agoThe discovery represents a potential new way to recruit the immune system to fight...
Novavax's Q1 Results Are Overshadowed by Its Sanofi Partnership | The Motley Fool
The Motley Fool· 1 day agoNovavax (NVAX 47.63%) released its first-quarter earnings report on May 10, and the vaccine-focused biotechnology company's numbers reflected notable progress. Novavax brings ...